Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mifepristone in abortion care.

Courtney Schreiber1, Mitchell Creinin

  • 1Contraception Research and Family Planning, University of Pittsburgh School of Medicine, Magee Womens Hospital, Pittsburgh, Pennsylvania 15213, USA. cschreiber@mail.magee.edu

Seminars in Reproductive Medicine
|February 17, 2005
PubMed
Summary

Mifepristone, combined with prostaglandin analogs, offers a highly effective and safe option for medication abortion up to 63 days gestation. This combination also aids in late first-trimester and second-trimester pregnancy termination.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring how California obstetrician-gynecologists interpret the fetal viability concept.

Contraception·2026
Same author

Navigating Choices: Pregnancy Options Counseling Experiences in Individuals With Opioid Use Disorder.

Journal of addiction medicine·2025
Same author

Application of a Multiplex Platform to Identify Novel Biomarkers for Pregnancy Location and Viability.

Reproductive sciences (Thousand Oaks, Calif.)·2023
Same author

Application of a Multiplex Platform to Identify Novel Biomarkers for Pregnancy Location and Viability.

Research square·2023
Same author

Tolerability and safety of the estetrol/drospirenone combined oral contraceptive: Pooled analysis of two multicenter, open-label phase 3 trials.

Contraception·2022
Same author

Society of Family Planning Committee statement on IUD nomenclature.

Contraception·2021

Area of Science:

  • Reproductive Medicine
  • Pharmacology

Background:

  • Mifepristone is a key medication used in medical abortion.
  • Prostaglandin analogs are commonly used to induce uterine contractions.

Observation:

  • Mifepristone enhances the efficacy of prostaglandin analogs in terminating pregnancies.
  • This combination is effective in early and late pregnancy stages.

Findings:

  • Outpatient medication abortion up to 63 days gestation with mifepristone and a prostaglandin analog achieves 92-99% success rates.
  • In the second trimester, mifepristone expedites induction time when combined with prostaglandins.
  • Mifepristone facilitates and improves the expulsive effects of prostaglandins.

Implications:

Related Experiment Videos

  • The use of mifepristone in abortion care provides valuable treatment flexibility for patients and clinicians.
  • Extensive research on mifepristone has significantly advanced the management of undesired and problem pregnancies.